PD-1 antibodies, such as pembrolizumab (Keytruda), nivolumab (Opdivo), and cemiplimab (Libtayo), as well as PD-L1 antibodies such as atezolizumab (Tecentriq), avelumab (Bavencio), and durvalumab (Imfinzi), have been approved by the FDA to treat cancer-mediated immune exhaustion [30]. Here, CD274 is linked to cancer.